Kilitch Drugs (India) Ltd
NSE:KILITCH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kilitch Drugs (India) Ltd
Interest Income Expense
Kilitch Drugs (India) Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kilitch Drugs (India) Ltd
NSE:KILITCH
|
Interest Income Expense
-₹57.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Interest Income Expense
-₹3.2B
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-17%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Interest Income Expense
-₹552.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Interest Income Expense
₹8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Interest Income Expense
-₹324.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Interest Income Expense
-₹2.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-1%
|
|
Kilitch Drugs (India) Ltd
Glance View
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.
See Also
What is Kilitch Drugs (India) Ltd's Interest Income Expense?
Interest Income Expense
-57.2m
INR
Based on the financial report for Dec 31, 2025, Kilitch Drugs (India) Ltd's Interest Income Expense amounts to -57.2m INR.
What is Kilitch Drugs (India) Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-47%
Over the last year, the Interest Income Expense growth was -20%. The average annual Interest Income Expense growth rates for Kilitch Drugs (India) Ltd have been -9% over the past three years , -47% over the past five years .
